|
Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study. |
|
F. Johannes P. van Valenberg |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
Employment - Advantage Healthcare Services (I) |
Stock and Other Ownership Interests - Johnson and Johnson; Johnson and Johnson; Johnson and Johnson |
Travel, Accommodations, Expenses - Intuitive Surgical; Photocure |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
Consulting or Advisory Role - Johnson & Johnson; Taris |
|
|
|
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
Honoraria - Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Diederik Meindert Somford |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; MSD |
|
Research Funding - Astellas Pharma; Besins Healthcare; Hinova Pharmaceuticals; Janssen; QED Therapeutics; Splash Pharmaceuticals |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Beigene; Bristol-Myers Squibb/Pfizer; Ferring; Janssen; MSD; Nucleix |
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; BeiGene; Bristol-Myers Squibb; Ferring; Janssen Oncology; MSD; oncodiag; photocure; Urogen pharma |